AFFYMETRIX (AFFX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX)

AFFX 14.01

0.0%

Apr 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boyce Burge who wrote (401)	7/3/1997 1:35:00 AM
From: Vector1	of 1728

Boyce, you asked for achievement Wednesday July 2 1:30 PM EDT Affymetrix GeneChip p53 assay available SANTA CLARA, Calif, July 2 (Reuter) - Affymetrix Inc said Wednesday that its GeneChip assay for use in detecting p53 gene mutations involved in human cancers has become commercially available in the U.S. for research applications. The assay is used to identify mutations on the p53 human gene. Mutations on the p53 gene are thought to play a significant role in human cancers, said product manager Dave Craford. Affymetrix said the GeneChip p53 assay has an accuracy of greater than 99 percent and is designed to be faster and easier to use than conventional gel-based sequencing. OncorMed Inc (ONM), a provider of gene-based cancer diagnostic services, has been a collaborator in the development of the assay and is expected to be one of the larger customers for the assay, Craford said. ``The Affymetrix GeneChip system represents a powerful new tool available for DNA analysis. The GeneChip p53 assay has broad potential use in research, clinical studies and pharmaceutical development, which we believe may lead to routine clinical use,'' OncorMed said in a joint statement with Affymetrix.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next